These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 18381408)
1. Mcl-1: a gateway to TRAIL sensitization. Kim SH; Ricci MS; El-Deiry WS Cancer Res; 2008 Apr; 68(7):2062-4. PubMed ID: 18381408 [TBL] [Abstract][Full Text] [Related]
2. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162 [TBL] [Abstract][Full Text] [Related]
3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Rosato RR; Almenara JA; Coe S; Grant S Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059 [TBL] [Abstract][Full Text] [Related]
4. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Itashiki Y; Harada K; Ferdous T; Yoshida H Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527 [TBL] [Abstract][Full Text] [Related]
5. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. Lee JT; Lee TJ; Park JW; Kwon TK Int J Oncol; 2009 May; 34(5):1455-60. PubMed ID: 19360359 [TBL] [Abstract][Full Text] [Related]
6. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624 [TBL] [Abstract][Full Text] [Related]
8. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493 [TBL] [Abstract][Full Text] [Related]
9. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385 [TBL] [Abstract][Full Text] [Related]
10. Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. Siegelin MD; Gaiser T; Habel A; Siegelin Y Neurosci Lett; 2009 May; 454(3):223-8. PubMed ID: 19429088 [TBL] [Abstract][Full Text] [Related]
11. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand. Oh B; Park S; Pak JH; Kim I Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523 [TBL] [Abstract][Full Text] [Related]
13. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840 [TBL] [Abstract][Full Text] [Related]
14. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553 [TBL] [Abstract][Full Text] [Related]
15. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830 [TBL] [Abstract][Full Text] [Related]
16. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092 [TBL] [Abstract][Full Text] [Related]
17. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684 [TBL] [Abstract][Full Text] [Related]
18. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Plantivaux A; Szegezdi E; Samali A; Egan L Ann N Y Acad Sci; 2009 Aug; 1171():38-49. PubMed ID: 19723036 [TBL] [Abstract][Full Text] [Related]
19. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Ashkenazi A; Holland P; Eckhardt SG J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940 [TBL] [Abstract][Full Text] [Related]
20. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]